Darren Cooke

🌟 Join us on June 4, 2024, for The Patent Office Comes to California symposium, presented by the IP Law Section. Experience it in-person at the USPTO’s Silicon Valley Regional Office or via live-stream! (register here >> https://lnkd.in/g_FFQQeJ) Hear from the USPTO and thought leaders from UC Law SF, Morrison Foerster, Google, Netflix, Genentech, Finnegan, Takara Bio, Altos Labs, Nutcracker Therapeutics, and Shiga International. Earn 6 hours of MCLE on top-of-mind patent topics including Section 101, Section 112, practicing before the PTAB, the Unitary Patent Package, practicing before the PTAB, and a special keynote address from the USPTO. 💼 Interested in becoming a sponsor? Let's connect! >> https://lnkd.in/giH3jnGR #PatentOffice #IPSymposium #USPTO #SponsorshipOpportunity 🚀 #MCLE #PTAB #USPTO

4

1 Comment

🌟 Join us on June 4, 2024, for The Patent Office Comes to California symposium, presented by the IP Law Section. Experience it in-person at the USPTO’s Silicon Valley Regional Office or via live-stream! (register here >> https://lnkd.in/g_FFQQeJ) Hear from the USPTO and thought leaders from UC Law SF, Morrison Foerster, Google, Netflix, Genentech, Finnegan, Takara Bio, Altos Labs, Nutcracker Therapeutics, and Shiga International. Earn 6 hours of MCLE on top-of-mind patent topics including Section 101, Section 112, practicing before the PTAB, the Unitary Patent Package, practicing before the PTAB, and a special keynote address from the USPTO. 💼 Interested in becoming a sponsor? Let's connect! >> https://lnkd.in/giH3jnGR #PatentOffice #IPSymposium #USPTO #SponsorshipOpportunity 🚀 #MCLE #PTAB #USPTO

7

🌟 Join us on June 4, 2024, for The Patent Office Comes to California symposium, presented by the IP Law Section. Experience it in-person at the USPTO’s Silicon Valley Regional Office or via live-stream! (register here >> https://lnkd.in/g_FFQQeJ) Hear from the USPTO and thought leaders from UC Law SF, Morrison Foerster, Google, Netflix, Genentech, Finnegan, Takara Bio, Altos Labs, Nutcracker Therapeutics, and Shiga International. Earn 6 hours of MCLE on top-of-mind patent topics including Section 101, Section 112, practicing before the PTAB, the Unitary Patent Package, practicing before the PTAB, and a special keynote address from the USPTO. 💼 Interested in becoming a sponsor? Let's connect! >> https://lnkd.in/giH3jnGR #PatentOffice #IPSymposium #USPTO #SponsorshipOpportunity 🚀 #MCLE #PTAB #USPTO

6

Common IP mistakes for biotech startups: 2. Making a public disclosure prior to filing a patent application (aka filing too late) This is by far the most common and also the most preventable mistake that we see startups make. To obtain a patent, your technology must be "novel" over the current state of the art. If you publicize your invention before filing a patent application, your invention is potentially no longer novel. It's important to keep in mind all of the possible types of public disclosures that might impact novelty of your invention, for example: ✔ Posters ✔ Abstracts ✔ Journal articles ✔ Conference presentations ✔ Websites ✔ Social media posts ✔ Sales or offers for sale Before making any disclosures about your invention, consult with an IP attorney to make sure that you are not jeopardizing your IP position!

15

2 Comments

Sharing Iain McIntyre's latest article, "Tutorial: Developing a patent portfolio." This May 31, 2024 article is part two of a two-part series explaining how to build a patent family and how to build on your patent application to ensure maximum patent coverage for your invention. Full article here: https://lnkd.in/djkJ3Jvr

5

I greatly agree to Clint Mehall's great article here, but since he asked here’s a slightly opposing view to spark the discussion: An LLM could easily be finetuned on all published applications of the client, selected competitors, or even the entire technical field. Who will come up with a better first draft of the claims, such a vastly literate LLM or an associate who has seen maybe a handful of relevant applications? Another use case is using the LLM as a brainstorming buddy to let it suggest workarounds for a given claim draft. Also this will improve quality, right? That said, my recommendation is to use AI to make suggestions, not decide anything obviously. Thinking that the entire process from the IDF to the full patent application can be automated with a 1-click AI, as some seem to propose, is a big mistake in my opinion. It should always be the human who decides on the claims in the end, not the AI. The reason is that deciding on the claims is a highly strategical task that has no analytically optimal solution. Yet, many parts of the patent drafting process can be greatly streamlined with AI, even with off-the-shelf LLMs. Coincidentally, I’m running a whole online seminar on this topic on Tuesday. Ticket sale ends tonight though: https://lnkd.in/djeMZKUc 

19

9 Comments

GPTs are a fantastic way of tying down AI use cases to repeatable, secure tools. We do something similar Curistica - perhaps a short workshop might be in order? Let me know if you’re interested in hearing more

13

15 Comments

Excited to have led the closing panel entitled "Bridging Science and Investment" in San Diego, CA. Joined by Dr. Sanjeev Thohan (Cogentis Therapeutics, Inc./Phoenix Molecular Designs) and Dr. Yuhua Ji (Grace Science, LLC ), we explored the intersection of scientific innovation and investment strategies. Key topics of this thought-provoking panel included: - Strategic investment approaches in the evolving biotech landscape - The critical role of venture capital in accelerating drug discovery - Innovative funding models for cutting-edge pharmaceutical research - The future of biotechnologies and the investment opportunities they present Thank you to the panelists for sharing their invaluable insights. Our discussion underscored the vital role of strategic investments in driving innovation and shaping the future of drug discovery and development. Together, we are paving the way for groundbreaking advancements in biotech. #biotechnology #MedicinalChemistry, #strategy #drugdevelopment Proventa International #Bio2024 BIO International Convention #DrugDiscovery #Investment #VentureCapital #Biotech #SanDiego American Association for Precision Medicine (AAPM) WISE World Investors & Entrepreneurs Society Agility Pharmaceuticals Precision BioPharma #ai #news

35

2 Comments

Now that the U.S. patent officials have weighed in on AI inventorship, health innovators want to know: What does it all mean for cutting-edge drug discovery? 🤔 Join Fenwick partners Antonia Sequeira, Hayan Yoon, and associates Pinar Erciyas Bailey, Malashaan Kind, and Fredrick Tsang as they unpack what’s changed, examine successful patent strategies, and identify potential pitfalls for AI-assisted drug R&D. 👉 Register now: https://bit.ly/4a4F2qS What are your burning questions about patents and AI-assisted drug discovery? #LifeSciences #ArtificialIntelligence #Patents

14

Thank you, Samar Shah and Jamie Brophy, for having me as a guest on the latest episode of your podcast, Patent Pending Made Simple! In this episode, Samar, a patent attorney, Jamie, a patent agent, and I cover the essential components required to successfully license a product idea. We discuss topics such as the significance of provisional patent applications, the step-by-step process of bringing an idea to market, the importance of thorough prior art searches, and many more. The Patent Pending Made Simple Podcast is a great resource for anyone navigating the complexities of patenting. One reviewer sums it up perfectly: “Patents can seem intimidating to inventors, but the hosts do a great job of making the concept accessible, easy to understand, and dare I say: fun” – JayRayJalen Thank you for hosting this valuable podcast where inventors can learn more about intellectual property, Samar and Jamie! https://lnkd.in/dwPqVxmG Give it a listen! #Patents #IntellectualProperty #Innovation #Success #Licensing #Podcast

23

7 Comments

🎉Congratulations to these outstanding #SoCal #startups for raising ~$443+ million in April 2024!💰Here they are👇 1️⃣ TORL BioTherapeutics, LLC - $158M 2️⃣ Flip - $144M 3️⃣ FloQast - $100M 4️⃣ Nominal - $27.5M 5️⃣ Full Glass Wine Co. - $14M 💸#investors, #VCfunds - Goldman Sachs, RA Capital Management, Avidity Partners, Vertex Ventures, Blue Owl Capital, Streamlined Ventures, Mubadala Capital, WestCap, WiL (World Innovation Lab), Sapphire Ventures, Meritech Capital, ICONIQ Capital, BDT & MSD Partners, XYZ Venture Capital, Overmatch Ventures, Lux Capital, HUMAN CAPITAL, Founders Fund, General Catalyst, Shea Ventures, et al. 🤖#industries #biotech, #mediatech, #retailtech, #ecommerce, #saas, #artificialintelligence, #software 🌴 #LosAngeles, #Glendale, #SantaMonica, #ShermanOaks, #ElSegundo, #OrangeCounty, #BeverlyHills, #Venice, #Pasadena, #Irvine, #CulverCity, #MarinaDelRey #venturecapital, #angelinvesting, #startups, #innovation, #tech Sources: Built In LA and Crunchbase https://lnkd.in/gfPuqYnJ

44

Underwhelming Reality of Using VR The release of Vision Pro and Quest 3 earlier this year temporarily reignited enthusiasm about the potential role of virtual reality. But the tech world is already back to focusing solely on AI. Why? To help answer the question, Voice of IP was able to convince Georgetown Professor Kasra Ferdows - one of the world’s leading tech futurists - to share an anecdote that illustrates his view of the underwhelming reality of using VR and the potential of AI to finally help advance its use. https://lnkd.in/ezDG4WiK

3

This will be a fascinating SynBioBeta talk - on how the combined tools of synthetic biology allowed Creyon Bio to build a successful drug in a few months 😳

13

Explore the latest IP blog, “Accelerating Innovation for New Inventors: Inside the First-Time Filer Expedited Patent Pilot Program,” by William J Hurles, which discusses the USPTO program which allows first time patent applicants to file a patent application along with a petition to make special without having to pay the fee or satisfy the special requirements that normally accompany such a petition. To read more, click here: https://bit.ly/4dkOx8b #iplaw

33

Breaking: The USPTO has just released a notice about a tech incident that happened between February 5, 2024, and March 29, 2024. According to the notice, the Office "inadvertently published non-public patent application titles and numbers that could be viewed during the recordation process by unauthorized individuals with access to registered Assignment Center accounts." The Office notified all impacted applicants about this incident, which has been fixed. To reassure the applicants, the Office noted: "Any improper access of the application information between the dates of February 5, 2024 and March 29, 2024, is not considered a publication of such applications under 35 U.S.C. 122(b). No rights in United States patents are threatened by this limited access to unpublished patent application information. While it is unlikely that the title could disclose the invention in a way that would constitute patent-defeating prior art in any jurisdiction, to the extent any issue is raised, the USPTO will assist applicants by confirming that the disclosure was erroneous and inadvertent." Read the notice https://lnkd.in/emZC5Vt2 #patent #disclosure #priorart

7

Looking back at the past 30 years, I remember myself doing science about 55-60 hours a week, and then helping venture capitalists and biotech start-ups about 70-80 h/week. Usually unsatisfied, sometimes exhausted, but pleased overall. This overexciting workaholism was somehow interrupted last year. I had less work and a lot of mountaineering, - climbed about 5.5 Chomolungma attitudes during the year. It feels like I have reached the stage at which it is a time to start sharing experiences and understanding of the universe. This week, I started to share by publishing an analytic report at SeekigAlpha about TG Therapeutics. This small biotech company has developed a third-to-market anti-CD20 mAb for the treatment of multiple sclerosis (MS). Along with the company, this report briefly touches upon current treatments for MS, the competitive landscape of therapeutics, and the uncertainties surrounding the development of new BTK inhibitors. https://lnkd.in/drAFx9vt

10

How will the LKQ v. GM decision affect design patent prosecution and litigation? On June 20th, WBD partner Brendan O'Dea will take a deep dive into this landmark decision on a webinar to discuss design patent obviousness. https://bit.ly/3RqKo9n

12

In a recent Law360 article, #CRAIntellectualProperty, James Donohue and Marie (Minasi) Sanyal provide an update on the VLSI-Intel case and identify more than 50 other patent infringement damages jury verdicts since 2018 that have similarly been overturned. Collectively, these overturned verdicts involve more than $10 billion in damages awards. The authors delve into various liability and damages issues that can lead to such verdicts, providing valuable insights for legal professionals and patent stakeholders. To read the full article, click here: https://crai.news/q3i

15